company background image
BNTX

BioNTech NasdaqGS:BNTX Stock Report

Last Price

US$158.59

Market Cap

US$38.5b

7D

-12.1%

1Y

-57.6%

Updated

11 Aug, 2022

Data

Company Financials +
BNTX fundamental analysis
Snowflake Score
Valuation5/6
Future Growth0/6
Past Performance5/6
Financial Health5/6
Dividends0/6

BNTX Stock Overview

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases.

BioNTech SE Competitors

Price History & Performance

Summary of all time highs, changes and price drops for BioNTech
Historical stock prices
Current Share PriceUS$158.59
52 Week HighUS$391.57
52 Week LowUS$117.08
Beta-0.076
1 Month Change-1.75%
3 Month Change-0.16%
1 Year Change-57.60%
3 Year Changen/a
5 Year Changen/a
Change since IPO1,013.69%

Recent News & Updates

Aug 05

BioNTech, Genmab expand pact to develop cancer immunotherapies

BioNTech (NASDAQ:BNTX) and Genmab (GMAB) are expanding their collaboration to develop and commercialize novel immunotherapies to treat patients with cancer. Under the new agreement, the companies will jointly develop and commercialize, subject to regulatory approval, monospecific antibodies using Genmab's HexaBody technology platform for various cancer indications. The first monospecific antibody candidate GEN1053/BNT313, is expected to enter clinical trials by the end of 2022. The companies said they will equally share the development costs and potential future profit from GEN1053/BNT313. The companies currently have two jointly developed investigational medicines: GEN1046/BNT311 is being evaluated in two phase 1/2 trials to treat advanced solid tumors, and in a phase 2 study in patients with non-small cell lung cancer. Meanwhile, GEN1042/BNT312 is being evaluated to treat metastatic or locally advanced solid tumors in a phase 1/2 study. BNTX +0.40% to $181.16, GMAB -0.39% to $35.87 premarket Aug. 5

Jul 27

Pfizer-BioNTech's new Omicron/ancestral strain COVID vaccine enters phase 2 trial

Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) said they began a phase 2 trial of a next-generation bivalent COVID-19 mRNA vaccine candidate BNT162b5 at a 30 µg dose level. The companies added that BNT162b5 consists of RNAs encoding enhanced prefusion spike proteins for the SARS-CoV-2 ancestral strain (wild-type) and an Omicron variant. The enhanced spike protein encoded from the mRNAs in BNT162b5 has been modified with the aim of increasing immune response which could better protect against COVID-19, the companies said in a July 27 press release. BNT162b5 will be evaluated in a U.S.-based trial enrolling ~200 people aged between 18 years and 55 years who have received one booster dose of a U.S.-authorized COVID-19 vaccine at least 90 days prior to their first study visit. The study does not include a placebo. The companies noted that this was the first of multiple vaccine candidates with an enhanced design which they plan to evaluate as part of a long-term COVID-19 vaccine strategy. Pfizer (PFE) and BioNTech's (BNTX) initial COVID-19 vaccine was BNT162b2, marketed as Comirnaty. BNTX +0.49% to 160.50 premarket July 27

Jul 25
Calculating The Fair Value Of BioNTech SE (NASDAQ:BNTX)

Calculating The Fair Value Of BioNTech SE (NASDAQ:BNTX)

Today we will run through one way of estimating the intrinsic value of BioNTech SE ( NASDAQ:BNTX ) by taking the...

Shareholder Returns

BNTXUS BiotechsUS Market
7D-12.1%1.2%1.3%
1Y-57.6%-23.0%-11.7%

Return vs Industry: BNTX underperformed the US Biotechs industry which returned -22.1% over the past year.

Return vs Market: BNTX underperformed the US Market which returned -11.6% over the past year.

Price Volatility

Is BNTX's price volatile compared to industry and market?
BNTX volatility
BNTX Average Weekly Movement8.7%
Biotechs Industry Average Movement12.5%
Market Average Movement7.8%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: BNTX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: BNTX's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20083,082Ugur Sahinhttps://www.biontech.de

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors.

BioNTech SE Fundamentals Summary

How do BioNTech's earnings and revenue compare to its market cap?
BNTX fundamental statistics
Market Cap€37.32b
Earnings (TTM)€11.75b
Revenue (TTM)€21.19b

3.2x

P/E Ratio

1.8x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
BNTX income statement (TTM)
Revenue€21.19b
Cost of Revenue€3.85b
Gross Profit€17.34b
Other Expenses€5.59b
Earnings€11.75b

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

Nov 07, 2022

Earnings per share (EPS)48.34
Gross Margin81.82%
Net Profit Margin55.44%
Debt/Equity Ratio0.008%

How did BNTX perform over the long term?

See historical performance and comparison